These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2723618

  • 1. Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein.
    Emini EA, Larson V, Eichberg J, Conard P, Garsky VM, Lee DR, Ellis RW, Miller WJ, Anderson CA, Gerety RJ.
    J Med Virol; 1989 May; 28(1):7-12. PubMed ID: 2723618
    [Abstract] [Full Text] [Related]

  • 2. Anti-PreS2 antibody assay for evaluating immune responses among recipients of recombinant hepatitis B PreS2 + S vaccine.
    Hurni WM, Roehm RR, Miller WJ.
    J Med Virol; 1990 Feb; 30(2):146-50. PubMed ID: 2313274
    [Abstract] [Full Text] [Related]

  • 3. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees.
    Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, Nakamura T, Miyakawa Y, Mayumi M.
    Proc Natl Acad Sci U S A; 1986 Dec; 83(23):9174-8. PubMed ID: 3466181
    [Abstract] [Full Text] [Related]

  • 4. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
    Nemecková S, Sroller V, Kunke D, Krystofová J, Kutinová L.
    Acta Virol; 1996 Dec; 40(5-6):273-9. PubMed ID: 9171455
    [Abstract] [Full Text] [Related]

  • 5. Antibody responses to preS components after immunization of children with low doses of BioHepB.
    Madalinski K, Sylvan SP, Hellström U, Mikolajewicz J, Zembrzuska-Sadkowska E, Piontek E.
    Vaccine; 2001 Oct 12; 20(1-2):92-7. PubMed ID: 11567751
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus.
    Ogata N, Cote PJ, Zanetti AR, Miller RH, Shapiro M, Gerin J, Purcell RH.
    Hepatology; 1999 Sep 12; 30(3):779-86. PubMed ID: 10462386
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A novel, recombinant triple antigen hepatitis B vaccine (Hepacare).
    Page M, Jones CD, Bailey C.
    Intervirology; 2001 Sep 12; 44(2-3):88-97. PubMed ID: 11509870
    [Abstract] [Full Text] [Related]

  • 11. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).
    Kuroda S, Fujisawa Y, Iino S, Akahane Y, Suzuki H.
    Vaccine; 1991 Mar 12; 9(3):163-9. PubMed ID: 1828318
    [Abstract] [Full Text] [Related]

  • 12. Antibody response to preS1 in hepatitis-B-virus-induced liver disease and after immunization.
    Coursaget P, Buisson Y, Bourdil C, Yvonnet B, Molinié C, Diop MT, Chiron JP, Bao O, Diop-Mar I.
    Res Virol; 1990 Mar 12; 141(5):563-70. PubMed ID: 2148981
    [Abstract] [Full Text] [Related]

  • 13. Subunit, recombinant and synthetic hepatitis B vaccines.
    Zuckerman AJ.
    Scand J Gastroenterol Suppl; 1985 Mar 12; 117():27-38. PubMed ID: 3912963
    [Abstract] [Full Text] [Related]

  • 14. The application of molecular biology to the development of novel vaccines.
    Kniskern PJ, Hagopian A, Burke P, Dunn N, Montgomery DL, Schultz LD, Schulman CA, Carty CE, Maigetter RZ, Wampler DE.
    Adv Exp Med Biol; 1989 Mar 12; 251():83-98. PubMed ID: 2532858
    [Abstract] [Full Text] [Related]

  • 15. Interactions of hepatitis B virus with hepatocytes: mechanism and clinical relevance.
    Theilmann L, Goeser T.
    Hepatogastroenterology; 1991 Feb 12; 38(1):10-3. PubMed ID: 1709133
    [Abstract] [Full Text] [Related]

  • 16. In vitro T cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2 + S vaccine recipients. Absence of cross-reactivity of subtypes at a major T cell recognition site.
    Cupps TR, Tibbles J, Hurni WM, Miller WJ, Ellis RW, Milich D, Wetter N.
    J Immunol; 1993 Sep 15; 151(6):3353-60. PubMed ID: 7690803
    [Abstract] [Full Text] [Related]

  • 17. Fine mapping and functional characterization of two immuno-dominant regions from the preS2 sequence of hepatitis B virus.
    Meisel H, Sominskaya I, Pumpens P, Pushko P, Borisova G, Deepen R, Lu X, Spiller GH, Krüger DH, Grens E.
    Intervirology; 1994 Sep 15; 37(6):330-9. PubMed ID: 8586531
    [Abstract] [Full Text] [Related]

  • 18. In vitro immune responses to hepatitis B surface antigens S and preS2 during acute infection by hepatitis B virus in humans.
    Cupps TR, Hoofnagle JH, Ellis RW, Miller WJ, Gerin JL, Volkman DJ, Haas-Smith SA.
    J Infect Dis; 1990 Mar 15; 161(3):412-9. PubMed ID: 2313122
    [Abstract] [Full Text] [Related]

  • 19. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype.
    Sobotta D, Sominskaya I, Jansons J, Meisel H, Schmitt S, Heermann KH, Kaluza G, Pumpens P, Gerlich WH.
    J Gen Virol; 2000 Feb 15; 81(Pt 2):369-78. PubMed ID: 10644835
    [Abstract] [Full Text] [Related]

  • 20. The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.
    Ferrari C, Penna A, Bertoletti A, Cavalli A, Valli A, Schianchi C, Fiaccadori F.
    J Clin Invest; 1989 Oct 15; 84(4):1314-9. PubMed ID: 2529268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.